Elsevier

Clinical Therapeutics

Volume 23, Issue 1, January 2001, Pages 127-145
Clinical Therapeutics

Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan

https://doi.org/10.1016/S0149-2918(01)80036-9Get rights and content

Abstract

Background: Patient-reported outcomes, such as treatment satisfaction, functional status, and health-related quality of life (HRQOL) are essential components of migraine research. Almotriptan is a new selective serotonin 1B/1D agonist triptan migraine treatment.

Objective: The purpose of this double-blind, multicenter, randomized, parallel-group study was to compare treatment satisfaction, functional status, and HRQOL of patients treated with oral almotriptan versus sumatriptan, the leading triptan on the market.

Methods: Migraine patients, aged 18 to 71 years, took equivalent oral doses of 12.5 mg almotriptan or 50 mg sumatriptan for the abortive treatment of a migraine headache. Treatment satisfaction differences between study groups were assessed using a 6-item measure to determine patients' satisfaction with pain relief and satisfaction with side effects 48 hours after drug administration. Functional status was assessed by analyzing the change in patients' ability to perform normal activities during the course of the migraine. HRQOL was compared between treatment groups at 24 hours using the Migraine Quality of Life Questionnaire. End points were assessed using entries from patients' 48-hour diaries.

Results: A total of 1173 patients were treated with almotriptan or sumatriptan. There were no significant differences between the 2 treatment groups in terms of satisfaction with pain relief; however, patients in the almotriptan group were significantly more satisfied (less bothered) with side effects than those receiving sumatriptan (P = 0.016). Functional status and HRQOL outcomes were not significantly different between groups.

Conclusions: In this study, migraine patients treated with almotriptan were significantly more satisfied with the side-effect profile of the drug than patients treated with sumatriptan. The results of this study may help inform practicing physicians and neurologists about the potential treatment satisfaction advantages of almotriptan.

References (29)

  • WS Hillis et al.

    Sumatriptan and chest pain

    Lancet

    (1993)
  • R Shikiar et al.

    The relation of patient satisfaction with treatment of otitis externa to clinical outcomes: Development of an instrument

    Clin Ther.

    (1999)
  • J Heywood et al.

    A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings

    Pharmacoeconomics

    (1997)
  • WF Stewart et al.

    Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

    JAMA

    (1992)
  • WH Visser et al.

    Risk factors for headache recurrence after sumatriptan: A study in 366 migraine patients

    Cephalalgia

    (1996)
  • NC Santanello et al.

    Improvement in migraine-specific quality of life in a clinical trial of rizatriptan

    Cephalalgia

    (1997)
  • C Dahlof et al.

    A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life

    Pharmacoeconomics

    (1997)
  • P Cortelli et al.

    A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity

    Pharmacoeconomics

    (1997)
  • J Bluchard et al.

    A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction

    Pharmacoeconomics

    (1997)
  • W Pryse-Phillips et al.

    A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache

    Can J Neurol Sci.

    (1992)
  • H Gobel et al.

    Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?

  • Migraine

    More than a headache

    Harv Health Lett.

    (1998)
  • V Pfaffenrath et al.

    Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan

    Headache

    (1998)
  • (1998)
  • Cited by (0)

    View full text